GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Gross Profit

RNXT (RenovoRx) Gross Profit : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Gross Profit?

RenovoRx's gross profit for the three months ended in Sep. 2024 was $0.00 Mil. RenovoRx's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. RenovoRx's gross profit for the three months ended in Sep. 2024 was $0.00 Mil. RenovoRx's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, RenovoRx's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.

RenovoRx had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


RenovoRx Gross Profit Historical Data

The historical data trend for RenovoRx's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Gross Profit Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
- - - - -

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RenovoRx's Gross Profit

For the Biotechnology subindustry, RenovoRx's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Gross Profit distribution charts can be found below:

* The bar in red indicates where RenovoRx's Gross Profit falls into.



RenovoRx Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

RenovoRx's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

RenovoRx's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

RenovoRx's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


RenovoRx  (NAS:RNXT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

RenovoRx had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


RenovoRx Gross Profit Related Terms

Thank you for viewing the detailed overview of RenovoRx's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303